The big respiratory players will be casting envious glances at the launch of Verona Pharma’s chronic obstructive pulmonary disorder (COPD) drug, Ohtuvayre, which is going from strength to strength.
Stellar Launch Of COPD Drug Puts Verona In Strong Partnering Position
The UK biotech has a potential blockbuster on its hands with Ohtuvayre and its strong sales showing so soon after launch could led to a lucrative licensing deal or possible takeover.
More from Earnings
More from Deals
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
• By
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.